Should we use statins in all patients with chronic kidney disease without dialysis therapy? The current state of knowledge

International Urology and Nephrology
Jacek RyszAndrzej Więcek

Abstract

The aim of this article was to present the most important matters associated with dyslipidemia treatment in CKD patients. Moreover, the most important recommendations of the current (2013) KDIGO clinical practice guideline for lipid management in chronic kidney disease are presented. Authors looked through the most recent large clinical trials and meta-analyses and presented their results. We searched using the electronic databases [MEDLINE, EMBASE, Scopus, DARE]. Additionally, abstracts from national and international cardiovascular meetings were studied. Analysis results suggest that statins exert beneficial effects on kidney since they considerably reduce 24 h urinary protein excretion and are associated with a rise in GFR. Beneficial effects of statins may be influenced by kidney disease stage, doses of medicine and treatment duration. Data suggest that statins are effective and safe for secondary prevention of CV events in individuals with mild CKD. Patients treated with statins had decreased frequency of major atherosclerotic events compared with placebo, reduced risk of CV mortality and deaths from all causes. Meta-analyses results suggest that statins are associated with lipid lowering, cardiovascular and anti-proteinur...Continue Reading

References

Oct 18, 1990·The New England Journal of Medicine·J E RossouwB M Rifkind
Mar 1, 1994·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·D C Wheeler, D B Bernard
Jul 1, 1993·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·M P O'DonnellW F Keane
Aug 1, 1993·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·A K CheungJ K Leypoldt
Feb 12, 1998·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·P JungersN K Man
Dec 5, 1998·The New England Journal of Medicine·UNKNOWN Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
Jul 21, 1999·Kidney International. Supplement·A YoshimuraT Ideura
Feb 19, 2002·Kidney International·Francesca MallamaciUNKNOWN CREED Investigators
Oct 3, 2002·Circulation·Hans L HillegeUNKNOWN Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group
Jan 17, 2003·Annals of Internal Medicine·Marcello TonelliUNKNOWN Cholesterol and Recurrent Events (CARE) Trial Investigators
Mar 4, 2003·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Stefano BianchiVito M Campese
Mar 19, 2003·Seminars in Dialysis·Katrin UhligMark J Sarnak
May 23, 2003·Journal of the American Society of Nephrology : JASN·Marcello TonelliUNKNOWN Cholesterol and Recurrent Events Trial Investigators
Sep 24, 2004·The New England Journal of Medicine·Alan S GoChi-yuan Hsu
Oct 20, 2004·Circulation·Folkert W AsselbergsUNKNOWN Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators
Jan 7, 2005·The New England Journal of Medicine·Paul M RidkerUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Inv
Feb 8, 2005·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Murray Epstein, Vito M Campese
Mar 10, 2005·The New England Journal of Medicine·John C LaRosaUNKNOWN Treating to New Targets (TNT) Investigators
Jun 7, 2005·Journal of the American Society of Nephrology : JASN·Vito M CampeseMurray Epstein
Jan 13, 2006·American Journal of Physiology. Renal Physiology·N D Vaziri
Jun 10, 2006·Journal of the American Society of Nephrology : JASN·Sabrina SandhuMarcello Tonelli
Jul 19, 2006·Annals of Internal Medicine·Kevin DouglasJeffrey L Jackson
Mar 9, 2007·Journal of the American Society of Nephrology : JASN·Xiang-Yang ZhuLilach O Lerman
Jul 28, 2007·Journal of the American Society of Nephrology : JASN·Robert N Foley, Allan J Collins
Apr 12, 2008·Journal of the American College of Cardiology·James ShepherdUNKNOWN TNT (Treating to New Targets) Investigators
Aug 5, 2008·Mayo Clinic Proceedings·James ShepherdUNKNOWN Treating to New Targets Steering Committee and Investigators
Aug 5, 2008·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Mahboob RahmanUNKNOWN ALLHAT Collaborative Research Group
Aug 30, 2008·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Marcello Tonelli
Feb 14, 2009·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Michael J KorenUNKNOWN ALLIANCE Investigators
Apr 17, 2009·The Cochrane Database of Systematic Reviews·Sankar D NavaneethanGiovanni F M Strippoli
Jun 23, 2009·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Helen M ColhounUNKNOWN CARDS Investigators
Oct 28, 2010·Expert Opinion on Pharmacotherapy·Maciej Banach, Jacek Rysz

❮ Previous
Next ❯

Citations

Jan 9, 2016·The American Journal of Cardiology·Tushar AcharyaIshak A Mansi
Jan 21, 2016·BioMed Research International·Yan-Feng HuangWei-Jie Zhang
Oct 9, 2015·Journal of Evaluation in Clinical Practice·Helle Wallach-KildemoesHálfdán Pétursson
Sep 5, 2015·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Allison B ReissJoseph Mattana
Jan 13, 2017·PloS One·Eun Yeong ChoJi Yong Jung
Sep 2, 2019·Clinical Chemistry and Laboratory Medicine : CCLM·Vanja Radišić BiljakUNKNOWN joint working group of Croatian Society of Medical Biochemistry and Laboratory Medicine and Croatian Chamber of Medical Bioc

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Related Papers

Clinical and Experimental Nephrology
Fabio FabbianFrancesco Portaluppi
International Urology and Nephrology
Agata Kujawa-SzewieczekGrzegorz Piecha
Nature Reviews. Nephrology
Vera Krane, Christoph Wanner
© 2022 Meta ULC. All rights reserved